MX2024002259A - Acido nucleico producido biologicamente para la produccion de vacunas. - Google Patents

Acido nucleico producido biologicamente para la produccion de vacunas.

Info

Publication number
MX2024002259A
MX2024002259A MX2024002259A MX2024002259A MX2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid sequence
cov
sars
biologically produced
Prior art date
Application number
MX2024002259A
Other languages
English (en)
Spanish (es)
Inventor
Enja Tatjana Kipfer
Thomas Klimkait
Christian Mittelholzer
Fabian Otte
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of MX2024002259A publication Critical patent/MX2024002259A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002259A 2021-09-09 2022-09-09 Acido nucleico producido biologicamente para la produccion de vacunas. MX2024002259A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21195643 2021-09-09
EP22179777 2022-06-19
PCT/EP2022/075140 WO2023036947A1 (en) 2021-09-09 2022-09-09 Biologically produced nucleic acid for vaccine production

Publications (1)

Publication Number Publication Date
MX2024002259A true MX2024002259A (es) 2024-03-06

Family

ID=83558295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002259A MX2024002259A (es) 2021-09-09 2022-09-09 Acido nucleico producido biologicamente para la produccion de vacunas.

Country Status (9)

Country Link
US (1) US20250188127A1 (enExample)
EP (1) EP4398935A1 (enExample)
JP (1) JP2024533378A (enExample)
KR (1) KR20240055051A (enExample)
AU (1) AU2022341555A1 (enExample)
CA (1) CA3224963A1 (enExample)
IL (1) IL310010A (enExample)
MX (1) MX2024002259A (enExample)
WO (1) WO2023036947A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220280633A1 (en) * 2019-07-30 2022-09-08 Verndari, Inc. Virus-like particle vaccines

Also Published As

Publication number Publication date
IL310010A (en) 2024-03-01
KR20240055051A (ko) 2024-04-26
AU2022341555A9 (en) 2024-01-25
WO2023036947A1 (en) 2023-03-16
AU2022341555A1 (en) 2024-01-18
JP2024533378A (ja) 2024-09-12
US20250188127A1 (en) 2025-06-12
EP4398935A1 (en) 2024-07-17
CA3224963A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
CO2022011685A2 (es) Vacunas de arn contra el coronavirus
WO2023283642A3 (en) Pan-human coronavirus concatemeric vaccines
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
PH12018500855A1 (en) Herpes simplex virus vaccine
BR112018008078A2 (pt) vacina de vírus influenza de amplo espectro
CO2017013310A2 (es) Dinucleótidos de purina cíclicos como moduladores de sting
CO2018012513A2 (es) Anticuerpos
DOP2017000175A (es) Dinucleótidos cíclicos útiles en el tratamiento del cáncer
PE20200849A1 (es) Anticuerpo multiespecifico
AR113257A1 (es) Virus chikungunya inmunogénico
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
BR112023019301A2 (pt) Formulações de vacina de coronavírus
ZA202100386B (en) Influenza virus hemagglutinin mutants
MX387420B (es) Producción de virus en cultivos celulares.
El Soufi et al. Circular code motifs in genomes of eukaryotes
MX2023007228A (es) Constructo de arn.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MX2024004252A (es) Vacunas antigripales multivalentes.
MX2022010928A (es) Ácido nucleico de cadena larga, completamente sintético para la producción de vacunas para protección contra coronavirus.
AR051923A1 (es) Secuencias de acidos nucleicos que codifican proteinas capaces de asociarse en particulas tipo virus
PE20251751A1 (es) Variantes de lfa3 y composiciones y usos de las mismas
BR112022009545A2 (pt) Método para produzir vírus influenza recombinantes
AR119105A1 (es) Célula mutante bloqueada mdbk irf3 / irf7 y su uso para producción de vacunas
MX2024012693A (es) Composiciones y metodos para la prevencion y el tratamiento de la infeccion por el virus de la rabia